CAMBRIDGE, Mass.--(BUSINESS WIRE)--NextPoint Therapeutics, a clinical-stage biotechnology company developing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the ...

St. Jude found 156 potential targets for chimeric antigen receptor (CAR) T--cell immunotherapy. Explore the discovery's promise to improve cancer therapies. Targeting anti-cancer therapy to affect ...